Medidur fluocinolone acetonide intravitreal implant: Additional Phase III data

Additional data from a double-blind, international Phase III trial in 129 patients with recurrent non-infectious uveitis affecting the posterior segment of the eye with or without anterior uveitis showed that 0.18 mg intravitreal Medidur led to a significantly lower rate of posterior uveitis at 12 months vs. sham control (26.4% vs. 85.7%, p<0.00000001). Additionally, 22.9% of Medidur-treated eyes had a >=15 letter improvement on the Early treatment Diabetic Retinopathy Study (ETDRS) eye chart from baseline to 12 months vs. 11.9% of eyes treated with sham control. pSivida previously reported that Medidur met the primary endpoint of a lower recurrence rate of posterior uveitis at 6 months vs. sham control (18.4% vs. 78.6%, p<0.00000001) (see BioCentury, Jan. 4). ...